

Wang-Zhong Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3709792/publications.pdf>

Version: 2024-02-01

34
papers

474
citations

759233

12
h-index

794594

19
g-index

35
all docs

35
docs citations

35
times ranked

479
citing authors

#	ARTICLE	IF	CITATIONS
1	Deep learning radiomics of dual-energy computed tomography for predicting lymph node metastases of pancreatic ductal adenocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1187-1199.	6.4	28
2	Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy. <i>JAMA Oncology</i> , 2022, 8, 553.	7.1	21
3	Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 706.	7.1	22
4	Individualized clinical target volume delineation and efficacy analysis in unilateral nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT): 10-year summary. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1931-1942.	2.5	6
5	Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 120-130.	0.8	27
6	Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival. <i>Biology of Sex Differences</i> , 2021, 12, 18.	4.1	10
7	Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis. <i>European Radiology</i> , 2021, 31, 4764-4773.	4.5	29
8	Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy. <i>ESMO Open</i> , 2021, 6, 100004.	4.5	6
9	Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 625534.	2.8	2
10	A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 817-828.	3.5	10
11	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 650292.	2.8	22
12	Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6044-6044.	1.6	4
13	Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 2225-2237.	3.5	5
14	Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 521-521.	1.6	1
15	Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 716-726.	10.7	42
16	A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4186-4194.	7.0	15
17	Benefit of chemotherapy in stage III nasopharyngeal carcinoma: Analysis of the surveillance, epidemiology, and end results database. <i>Oral Oncology</i> , 2021, 117, 105284.	1.5	12
18	Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2124721.	5.9	14

#	ARTICLE	IF	CITATIONS
19	Trajectories of EBV DNA and identifying the potential long-term survivors in metastatic nasopharyngeal carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 3946-3955.	1.4	0
20	Prognostic value of early radiological response to first-line platinum-containing chemotherapy in patients with metastatic nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2020, 9, 920-930.	2.8	4
21	Educational disparities in nasopharyngeal carcinoma survival: Temporal trends and mediating effects of clinical factors. <i>Clinical and Translational Medicine</i> , 2020, 10, e134.	4.0	0
22	Prognostic and Treatment Guiding Significance of MRI-Based Tumor Burden Features and Nodal Necrosis in Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 537318.	2.8	3
23	MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it. <i>Radiotherapy and Oncology</i> , 2020, 145, 101-108.	0.6	12
24	Prognostic models for prediction of overall survival after first-line platinum-based chemotherapy for primary metastatic nasopharyngeal carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17501-e17501.	1.6	0
25	The CXCL5/CXCR2 axis contributes to the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells by activating ERK/GSK-3 β /snail signalling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 85.	8.6	36
26	Development and validation of an endoscopic images-based deep learning model for detection with nasopharyngeal malignancies. <i>Cancer Communications</i> , 2018, 38, 1-11.	9.2	43
27	Concurrent Chemoradiotherapy versus Intensity-modulated Radiotherapy Alone for Elderly Nasopharyngeal Carcinoma Patients with Pre-treatment Epstein-Barr Virus DNA: A Cohort Study in an Endemic Area with Long-term Follow-up. <i>Journal of Cancer</i> , 2018, 9, 3023-3031.	2.5	10
28	The prognostic significance of carcinoma-associated fibroblasts and tumor-associated macrophages in nasopharyngeal carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 1935-1946.	1.9	34
29	The plasma Epstein-Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878233.	3.2	15
30	Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. <i>Cancer Communications</i> , 2018, 38, 1-10.	9.2	26
31	Platinum-based concurrent chemotherapy remains the optimal regimen for nasopharyngeal carcinoma: a large institutional-based cohort study from an endemic area. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2231-2243.	2.5	9
32	Comparison between lobaplatin and cisplatin plus 5-fluorouracil combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized phase III clinical trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6029-6029.	1.6	0
33	A retrospective study of 606 cases of nasopharyngeal carcinoma with or without oropharyngeal candidiasis during radiotherapy. <i>PLoS ONE</i> , 2017, 12, e0182963.	2.5	6
34	Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma—Reply. <i>JAMA Oncology</i> , 0, , .	7.1	0